Asset Details
Do you wish to reserve the book?
Metformin upregulates mitophagy in patients with T2DM: A randomized placebo‐controlled study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Metformin upregulates mitophagy in patients with T2DM: A randomized placebo‐controlled study
Do you wish to request the book?
Metformin upregulates mitophagy in patients with T2DM: A randomized placebo‐controlled study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Metformin upregulates mitophagy in patients with T2DM: A randomized placebo‐controlled study
2020
Overview
Impaired mitochondrial autophagy (mitophagy) and NLRP3 inflammasome activation have been incriminated in the pathogenesis of T2DM. Metformin besides being an insulin sensitizer also induces autophagy; however, its effect on mitophagy and NLRP3 activation in patients with T2DM still remains elusive. Forty‐five drug‐naïve T2DM patients with HbA1C 7%‐9% (53‐75 mmol/mol) were randomly assigned to receive either metformin, voglibose, or placebo for 3 months, and were also recommended for lifestyle intervention programme (n = 15 each). Mitochondrial oxidative stress (MOS) parameters, qPCR and immunoblotting of mitophagy‐related markers (PINK1, PARKIN, MFN2, NIX, LC3‐II, LAMP2), p‐AMPKα (T172), and NLRP3 proteins, as well as transmission electron microscopy (TEM) for assessing mitochondrial morphology were performed in the mononuclear cells of study patients. Both metformin and voglibose showed a similar efficacy towards the reduction in HbA1c and MOS indices. However, multivariate ANCOVA divulged that mRNA and protein expression of mitophagy markers, NLRP3 and p‐AMPKα (T172), were significantly increased only with metformin therapy. Moreover, PINK1 expression displayed a significant positive association with HOMA‐β indices, and TEM studies further confirmed reduced distortions in mitochondrial morphology in the metformin group only. Our observations underscore that metformin upregulates mitophagy and subsequently ameliorates the altered mitochondrial morphology and function, independent of its glucose‐lowering effect. Further, restoration of normal mitochondrial phenotype may improve cellular function, including β‐cells, which may prevent further worsening of hyperglycaemia in patients with T2DM.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Cytology
/ Diabetes
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - genetics
/ Diabetes Mellitus, Type 2 - pathology
/ Fasting
/ Female
/ Glucose
/ Humans
/ Inositol - analogs & derivatives
/ Insulin
/ Kinases
/ Male
/ Meals
/ Membrane Potential, Mitochondrial - drug effects
/ Mitochondria - ultrastructure
/ mRNA
/ nucleotide‐binding oligomerization domain‐like receptor family pyrin domain‐containing 3 (NLRP3)
/ Original
/ Placebos
/ Proteins
/ PTEN-induced putative kinase
/ Reactive Oxygen Species - metabolism
